Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update
05:00pm, Thursday, 09'th Feb 2023 Zacks Investment Research
Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.
2 Top Biotech Stocks to Buy Right Now
02:37pm, Thursday, 09'th Feb 2023 The Motley Fool
These two companies each pay market-beating dividends to shareholders.
JEPI Is The Name, High Yield Is The Game
12:00pm, Thursday, 09'th Feb 2023 Seeking Alpha
JEPI is a covered call exchange-traded fund that invests in low volatility stocks. Read more to see my thoughts on the ETF and my recommendation.
Big Pharma's Big Gains
02:14am, Thursday, 09'th Feb 2023
Given enough time, stock in pharmaceutical giants has yielded life-altering gains. Because of its popular and widely distributed COVID-19 vaccine, Pfizer has sparked more controversy than other stocks
Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx
04:56pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.
A Look at Pharma ETFs Post Q4 Earnings
03:05pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.
2 Top Biotech Stocks to Buy in February
02:45pm, Wednesday, 08'th Feb 2023 The Motley Fool
Biotech stocks aren't all created equal -- these two are the best of the bunch.
Could This Indication Provide a Lift for Bristol Myers Squibb's Stock?
02:00pm, Monday, 06'th Feb 2023 The Motley Fool
Bristol Myers' Sotyktu recently moved one step closer to its first approval in the European Union.
1 Company Bucks the Office REIT Trend With Higher Rents and Earnings
12:46pm, Monday, 06'th Feb 2023 The Motley Fool
Life sciences companies may be more immune to work-from-home shifts.
Biogen: What To Do Ahead Of Q4 2022 Financial Report
07:12am, Monday, 06'th Feb 2023 Seeking Alpha
Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. Find out why BIIB stock is a Hold.
'The Big Short' Michael Burry Says Sell, Inflation Is Not Over
02:00pm, Saturday, 04'th Feb 2023 Seeking Alpha
Michael Burry just sent a scary warning. He thinks that the country is broke and that the rally will be short-lived. Click here for our view of Burry's caution.
Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?
09:26am, Saturday, 04'th Feb 2023
Bristol Myers Squibb has solid replacements for its blockbusters that are facing a patent cliff.
Company News for Feb 3, 2023
02:11pm, Friday, 03'rd Feb 2023 Zacks Investment Research
Companies in The news Are: META, BMY, PH, CAH.
What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb
12:01pm, Friday, 03'rd Feb 2023 Benzinga
Analysts have provided the following ratings for Bristol-Myers Squibb (NYSE:BMY) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
3
2
0
0
Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales
07:59pm, Thursday, 02'nd Feb 2023 Zacks Investment Research
Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.
